Skip to main content

Table 4 Receptor discordance

From: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options

ER

 Concordant

105 (79.6%)

 Discordant

27 (20.4%)

 Gain

6 (4.5%)

 Loss

21 (15.9%)

PR

 Concordant

82 (62.1%)

 Discordant

50 (37.8%)

 Gain

6 (4.5%)

 Loss

44 (33.2%)

HER2

 Concordant

128 (97%)

 Discordant

4 (3%)

 Gain

2 (1.5%)

 Loss

2 (1.5%)

 Subtype

N (%)

 Concordant

101 (76.5%)

 Discordant

31 (23.5%)